Skip to content

Pfizer PFE EV / sales

EV / sales at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
3.3×-0.1×
Eli Lilly logo
Eli LillyLLY
11.9×-4.0×
Johnson & Johnson logo
Johnson & JohnsonJNJ
6.5×+1.8×
Merck & Co. logo
Merck & Co.MRK
5.2×+1.2×
Amgen logo
AmgenAMGN
6.6×+0.1×
Incyte logo
IncyteINCY
2.9×+0.6×

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+5.0%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$147.73B+11.1%
Enterprise value$210.4B+9.2%
P/E12.2×
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%

Returns & leverage

See full
Return on equity10.6%
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Calculated from Pfizer’s reported figures.

Based on the most recent quarter.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's EV / sales?
Pfizer (PFE) reported EV / sales of 3.5× in Q1 2026.
How has Pfizer's EV / sales changed year-over-year?
Pfizer's EV / sales increased by 7.7% year-over-year, from 3.3× to 3.5×.
What is the long-term trend for Pfizer's EV / sales?
Over 4 years (2021 to 2025), Pfizer's EV / sales has grown at a -8.5% compound annual growth rate (CAGR), from 18.5× to 13×.
What does EV / sales mean?
What the whole business costs relative to its annual sales.
How do you interpret EV / sales?
A fallback valuation gauge for pre-profit or cyclical firms. Like P/S, only comparable across similar-margin businesses, but it accounts for debt and cash unlike P/S.
How does EV / sales compare across companies?
Compare within a margin cohort; the debt-and-cash adjustment makes it cleaner than P/S for leveraged firms.